EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Merging evans syndrome with mucopolysaccharidosis type II: a case report

Xinrui Wang, Jing Zhang, Yanhui Tang, Chunyan Liu, Peng Hu, You Yang, Hongying Chen

Frontiers in Pediatrics · 04.05.2026 · 14

DOI: 10.3389/fped.2026.1784387 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Pediatrics, online erschienen am 04.05.2026. Verfasst von Xinrui Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, The Affiliated Hospital of Southwest Medical University, Sich…. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan Provincial Science and Technology Support Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucopolysaccharidosis type II (MPS II) is an X-linked recessive lysosomal storage metabolic disorder caused by pathogenic mutations in the iduronate-2-sulfatase (IDS) gene. Herein, we report the case of a 2-year-old male patient diagnosed with concurrent Evans syndrome (ES) and MPS II, who presented with severe anemia, thrombocytopenia, recurrent respiratory tract infections, and typical clinical manifestations of MPS II. Laboratory examinations showed decreased hemoglobin (Hb) and platelet (PLT) counts, a positive direct Coombs test, presence of anti-platelet antibodies, elevated urinary glycosaminoglycan levels, and complete absence of IDS enzyme activity. Whole exome sequencing identified a novel compound heterozygous nonsense mutation in the IDS gene: c.380_383dup GCTA, p.Y128X. The patient received hematopoietic stem cell transplantation (HSCT) and underwent long-term follow-up. During the follow-up period, the patient's IDS enzyme activity returned to normal levels, and no further recurrence of ES was observed. This study reports a novel pathogenic mutation of the IDS gene, and represents the first documented case of concurrent ES and MPS II in a toddler. HSCT has been confirmed to be an effective therapeutic strategy for this extremely rare comorbid condition. Additionally, we discuss the potential pathogenic association between mucopolysaccharidosis (MPS) and ES, and present a systematic summary of the clinical management of this patient, to provide a reference for improved identification and treatment of similar clinical cases in the future.

Schlagwörter

Stichwörter der Autor:innen

case reportevans syndrome (ES)hematopoietic stem cell transplantation (HSCT)iduronate-2-sulfatase (IDS)mucopolysaccharidosis type II (MPS II)

Autor:innen und Institutionen

  • Department of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, The Affiliated Hospital of Southwest Medical University, Sichuan Clinical Research Center for Birth Defects, Luzhou, Sichuan, China.
  • Department of Pediatrics Growth and Health Care, The Guangan People's Hospital, Guangan, Sichuan, China.
  • Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.

Förderung

  • Sichuan Provincial Science and Technology Support Program

Zitieren

APA

Wang, X., Zhang, J., Tang, Y., Liu, C., Hu, P., Yang, Y., & Chen, H. (2026). Merging evans syndrome with mucopolysaccharidosis type II: a case report. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1784387

Vancouver

Wang X, Zhang J, Tang Y, Liu C, Hu P, Yang Y, et al. Merging evans syndrome with mucopolysaccharidosis type II: a case report. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1784387

BibTeX
@article{Wang2026,
  author = {Wang, Xinrui and Zhang, Jing and Tang, Yanhui and Liu, Chunyan and Hu, Peng and Yang, You and Chen, Hongying},
  title = {Merging evans syndrome with mucopolysaccharidosis type II: a case report},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.1784387}
}
Kostenlos starten →